NCT01405560View on ClinicalTrials.gov

Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 2, 2011

Primary Completion Date

March 29, 2013

Study Completion Date

March 29, 2013

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Vaniprevir

Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks

BIOLOGICAL

peg-IFN

Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks

DRUG

ribavirin

Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01405560 - Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045) | Biotech Hunter | Biotech Hunter